Inhibikase Therapeutics, Inc. (IKT) Insider Ownership

Historic Insider Ownership Trends

As of March 23, 2026, the three largest insider holders of IKT are Capital Life Sciences Pulse Fund Ii, L.P. Sands (TenPercentOwner, 13.02Mn shares), Milton H. Werner (President And Ceo, 5.34Mn shares), Roberto Bellini (Director, 1.46Mn shares).

Top Direct Holders

Insider ownership data is derived from the last 60 months of Form 4 SEC filings.
Holder Position Shares (Direct) Shares (Indirect) Report Date
Capital Life Sciences Pulse Fund Ii, L.P. Sands 13,018,965 0 24 Nov, 2025
Milton H. Werner President And Ceo 5,335,433 0 16 Aug, 2022
Roberto Bellini 0 1,460,000 23 Oct, 2024
Christopher Cabell President Head Of Rd 676,564 0 24 Feb, 2026
Vincent Aurentz 510,596 0 24 Feb, 2026
Amit Munshi 0 365,000 23 Oct, 2024
Arvind Kush 145,000 0 23 Oct, 2024
Amit Munshi 38,176 0 24 Feb, 2026
Milton H. Werner President And Ceo 0 23,589 19 Nov, 2021

* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.

Recent Insider Transactions

Detailed insider trading activity based on Form 4 SEC filings.
Download Data
Transaction Date Insider Name Security Class Transaction Type Shares Traded Price Shares Remaining Ownership Code
21 Feb, 2026 Christopher Cabell Common Stock D 338,282 $0.00 676,564 D D
21 Feb, 2026 Amit Munshi Common Stock D 19,089 $0.00 38,176 D D
21 Feb, 2026 Vincent Aurentz Common Stock D 255,299 $0.00 510,596 D D
05 Jan, 2026 Mark T Iwicki Stock Option (Right to Buy) A 4,982,706 $0.00 4,982,706 D A
05 Jan, 2026 David Mcintyre Stock Option (Right to Buy) A 986,319 $0.00 986,319 D A
05 Jan, 2026 Christopher Cabell Stock Option (Right to Buy) A 900,117 $0.00 900,117 D A
21 Nov, 2025 Capital Life Sciences Pulse Fund Ii, L.P. Sands Common Stock A 2,068,965 $1.45 13,018,965 D P
30 Jun, 2025 Vincent Aurentz Stock Option (Right to Buy) A 108,176 $0.00 108,176 D A
30 Jun, 2025 Arvind Kush Stock Option (Right to Buy) A 108,176 $0.00 108,176 D A
30 Jun, 2025 Amit Munshi Stock Option (Right to Buy) A 108,176 $0.00 108,176 D A
30 Jun, 2025 David Canner Stock Option (Right to Buy) A 108,176 $0.00 108,176 D A
30 Jun, 2025 Roberto Bellini Stock Option (Right to Buy) A 108,176 $0.00 108,176 D A
14 Apr, 2025 David Mcintyre Stock Option (Right to Buy) A 1,775,539 $0.00 1,775,539 D A
21 Feb, 2025 Mark T Iwicki Stock Option (Right to Buy) A 602,346 $0.00 602,346 D A
21 Feb, 2025 Vincent Aurentz Stock Option (Right to Buy) A 134,427 $0.00 134,427 D A
21 Feb, 2025 Christopher Cabell Stock Option (Right to Buy) A 1,100,705 $0.00 1,100,705 D A
14 Feb, 2025 Mark T Iwicki Stock Option (Right to Buy) A 4,373,857 $0.00 4,373,857 D A
14 Feb, 2025 Roy Lester Freeman Stock Option (Right to Buy) A 22,640 $0.00 22,640 D A
14 Feb, 2025 Arvind Kush Stock Option (Right to Buy) A 56,600 $0.00 56,600 D A
14 Feb, 2025 Amit Munshi Stock Option (Right to Buy) A 56,600 $0.00 56,600 D A